Moderna reviews clinical trial programs across portfolio at 2022 r&d day
Interim data from phase 1/2 propionic acidemia (pa) multi-dose paramount trial shows mrna-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit interim data from phase 1/2 glycogen storage disease 1a (gsd1a) single-dose ba1ance trial shows mrna-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit moderna announces a new development candidate, mrna-3139, for ornithine transcarbamylase (otc) deficiency, a rare genetic disorder phase 3 clinical trial of rsv vaccine, mrna-1345, has enrolled more than 24,000 of the 34,000-participant target phase 3 immunogenicity and safety study of flu vaccine, mrna-1010, is fully enrolled; company to pursue accelerated approval pathway in 2023 company is on track to report data from its phase 2 personalized cancer vaccine (pcv) study in 4q 2022 cambridge, ma / accesswire / september 8, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced advances across its portfolio of mrna programs presented at the company's annual r&d day. "we continue to make significant progress in accelerating our pipeline.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission